Eli Lilly Retevmo Cuts Cancer Recurrence or Death Risk by 83% in Phase 3 Trial of 151 NSCLC Patients

On May 31, 2026, Eli Lilly (NYSE: LLY) delivered one of the most significant oncology data readouts of the year. The Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) met its primary endpoint with results that are difficult to overstate. In 151 patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC), Retevmo reduced the risk of disease recurrence or death by 83% versus placebo. The data was simultaneously published in the New England Journal of Medicine and presented during the Plenary Session at the 2026 ASCO Annual Meeting in Chicago, Illinois, the highest-profile stage in oncology science. LLY stock trades at $1,105.00 with a market cap of $1.04 trillion.

What LIBRETTO-432 Actually Showed

The numbers from this trial are striking at every level.

At a median follow-up of 24 months, the 24-month event-free survival (EFS) rate was 92% for selpercatinib versus 61% for placebo in the primary analysis population of patients with stage II–IIIA disease. Median EFS was not reached in the selpercatinib group, compared to 31.8 months for placebo. In plain terms: after two years, 92 out of every 100 patients on Retevmo were alive and cancer-free. Only 61 out of 100 on placebo achieved the same outcome.

The hazard ratio was 0.172 (95% CI, 0.058–0.509; P = .0003), confirming the result was highly statistically significant. The EFS benefit was consistent across patient subgroups and confirmed by blinded independent central review.

How the Trial Was Designed

The trial enrolled 151 patients who were randomized 1:1 to receive either selpercatinib or placebo as adjuvant therapy for RET fusion-positive NSCLC. The primary endpoint was EFS as assessed by investigators in the primary analysis population, which was composed of patients with stage II–IIIA RET fusion-positive NSCLC.

Participants were treated with selpercatinib 160 mg twice daily or placebo for up to three years following surgery or radiotherapy, with or without adjuvant chemotherapy. A total of 3,446 patients were assessed for eligibility across 65 sites in 22 countries, enrolled between January 2022 and March 2025, with a database cutoff of January 2026. The most common reason for exclusion was the absence of a RET fusion (n = 3,149), reflecting the relative rarity of this molecular subtype.

Why RET Fusion Testing Now Matters at Every Stage

RET fusions are seen in 1% to 2% of patients with NSCLC. The results serve to establish RET fusions as a key biomarker to test for across all disease stages. That is the clinical shift this trial creates. Previously, targeted RET therapy was largely associated with advanced or metastatic disease. LIBRETTO-432 now positions Retevmo as a potential standard of care in early-stage, post-surgery settings with a meaningfully different and larger patient population.

Lilly plans to submit LIBRETTO-432 results to global health authorities for review. According to Lilly, the Phase 3 findings may support the use of selpercatinib as adjuvant therapy in early-stage RET fusion-positive NSCLC and emphasize comprehensive biomarker testing at lung cancer diagnosis.

Analysts Review: What It Means for Eli Lilly’s Oncology Pipeline

This trial win arrives at a moment when Eli Lilly is already operating from a position of financial strength. Q1 2026 revenue grew 56% year-on-year, and management raised full-year revenue guidance to $82–$85 billion, implying 28% growth at the midpoint. BofA holds a Buy rating with a price target of $1,251. The 52-week range for LLY runs from $623.78 to $1,149.10, with the all-time high set on May 28, 2026.

LIBRETTO-432 does not move Eli Lilly’s near-term revenue needle the way Mounjaro or Zepbound do. RET fusion-positive NSCLC is a rare subtype. But it confirms the depth and execution quality of Eli Lilly’s oncology division, and a regulatory submission to support adjuvant use of Retevmo would expand the drug’s addressable market in a meaningful way.

Disclaimer

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.